HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Michael Todd, ‘Where Science Meets Nature,’ Meets FDA Warning Letter

This article was originally published in The Rose Sheet

Executive Summary

Port St. Lucie, Fla.-based firm’s Intensive Eye Treatment and Knu Anti-Aging Face Lift Serum are unapproved drugs based on claims featured online, FDA says. The July 18 warning letter, posted to the agency’s website Aug. 16, was one of at least 10 that issued to skin-care companies in July.

You may also be interested in...



FDA’s July Warning Letters To Skin-Care Marketers Continue To Surface

Add Menscience Androceuticals, La Bella Figura and Healing Scents to the list of skin-care marketers hit with FDA warning letters in July. The agency’s policy is to wait for warning letter recipients to acknowledge receipt before posting the communications to its website.

FDA Warning Letter Barrage Continues With Five More To Close July

At least nine skin-care marketers received FDA warning letters in July for unapproved drug claims. In the month’s final two weeks, recipients included companies behind the Freeze 24-7 Instant Targeted Wrinkle Treatment and a Resurgent Stem Cell Firming Activator, among others.

House Of Representatives Concerned Over Complex Generics

The Committee on Energy and Commerce of the US House of Representatives has requested a set of documents from the FDA in order to assess whether the agency is doing enough to address the challenge of approving complex generics within its existing authorities, or whether additional authority is needed.

Topics

UsernamePublicRestriction

Register

RS108510

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel